PLTR is trading 2.2% down at $114.17 as it faces renewed pressure from UK parliamentary scrutiny. - A UK parliamentary committee raised concerns about the company's public-sector role, citing an “unacceptable point of weakness” and questioning its £240M no-bid Ministry of Defence contract. - Reports indicated that most UK NHS platform benefits were concentrated in only a few hospital trusts, adding to doubts about Palantir's healthcare scale and increasing political risk. - The decline is also influenced by broader market reassessment of AI valuations.